Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
PharmacoEconomics 40, 979–988 (2022).
Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Journal of Medical Economics 2022, 25:1, 1092-1100
Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors
Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities: A Perspective from Directors of Nursing
Vibegron for the treatment of patients with dry and wet overactive bladder: a subgroup analysis from the EMPOWUR trial.
Int J Clin Pract. 2022;2022:(9 pages). doi:10.1155/2022/6475014
An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder.
Ther Clin Risk Manag. 2022;18:171-182. doi:10.2147/TCRM.S310371
Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR.
Adv Ther. 2022;39:959-970. doi:10.1007/s12325-021-01972-8
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.
Blood Press Monit. 2022;27(2):128-134. doi:10.1097/MBP.0000000000000572
Efficacy of vibegron and mirabegron for overactive bladder: A systematic literature review and indirect treatment comparison.
Kennelly et al. Adv Ther. 2021
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug-Drug Interactions
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer
Ther Clin Risk Manag. 2021
Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study.
Int J Clin Pract. 2021;75(5):e13937. doi:10.1111/ijcp.13937
Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 years: subpopulation analysis from the EMPOWUR randomized, international, phase Ill study.
Drugs Aging. 2021;38:137-146. doi:10.1007/s40266-020-00829-z
Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta‐analysis
Optimizing Nonsurgical Treatments of Overactive Bladder in the United States
Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor...
Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).
J Urol. Published online December 28, 2020. doi:10.1097/JU.0000000000001574
Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.
Int Urol Nephrol. 2020;52(12):2215-2221. doi:10.1007/s11255-020-02536-5
Evaluating vibegron for the treatment of overactive bladder.
Expert Opin Pharmacother. 2020 Sep 29:1-9. [Epub ahead of print] doi:10.1080/14656566.2020.1809652
International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR.
J Urol. 2020;204(2):316-324. doi:10.1097/JU.0000000000000807
Effects of vibegron, a novel β3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction.
Eur J Pharmacol. Published online July 5, 2020. doi:10.1016/j.ejphar.2020.173096
The efficacy and safety of vibegron in treating overactive bladder: a systematic review and pooled analysis of randomized controlled trials.
Neurourol Urodyn. 2020;39(5):1255-1263. doi:10.1002/nau.24387
Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
BJU Int. 2020;125(5):709-717. doi:10.1111/bju.15020
Efficacy of novel β3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.
Int J Urol. 2019;26(3):369-375. doi:10.1111/iju.13877
Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats.
Eur J Pharmacol. Published online December 1, 2019. doi:10.1016/j.ejphar.2019.172727
Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial.
Eur Urol. 2019;75(2):274-282. doi:10.1016/j.eururo.2018.10.006
Vibegron: first global approval.
Drugs. 2018;78(17):1835-1839. doi:10.1007/s40265-018-1006-3
Synthesis of vibegron enabled by a ketoreductase rationally designed for high pH dynamic kinetic reduction.
Angew Chem Int Ed Engl. 2018;57(23):6863-6867. doi:10.1002/anie.201802791
Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study.
Eur Urol. 2018;73(5):783-790. doi:10.1016/j.eururo.2017.12.022
Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study.
Int J Urol. 2018;25(7):668-675. doi:10.1111/iju.13596